Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Grifols SA
GRFS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.15
-0.05
-0.61%
al cierre: Nov 20, 4:00 PM EST
$8.14
-0.01
-0.12%
After hour: 4:31 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Grifols Financials
Grifols (GRFS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Grifols Reports Q3 Revenue €2.04B, Up 8.4% YoY; Adj EBITDA €538M; Says On Track To Deliver FY26 Outlook
https://www.grifols.com/en/view-news/-/news/grifols-increases-revenue-by-8-4-to-eur-2040-million-and-grows-net-profit-by-28-to-eur-162m-in-q326
Benzinga Newsdesk
PRO
Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY
https://www.grifols.com/en/view-news/-/news/grifols-increases-q1-2026-revenues-by-3-3-to-1-7billion-and-net-profit-21-9-to-73-million
Benzinga Newsdesk
PRO
Grifols S.A. Q2 Revenue €1.89 Billion Up From €1.82 Billion YoY; EPS €0.17 Up From €0.02 YoY
Benzinga Newsdesk
PRO
Grifols Q1 Revenue €1.786 Billion; Adjusted EBITDA €400 Million; Q1 Net Income €60 Million; Confirms 2025 Guidance; Says On Track To Launch Fibrinogen In Europe In Q4'25 And In The U.S. In H1'26, Following FDA Approval; Expects To Share Greater Detail In 2025 Due To Impact Of Inflation Reduction Act On Its Financial Results
https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D
Benzinga Newsdesk
PRO
Grifols CFO Says Revenues Expected To Grow 7% In 2025 To €7.7 Billion Excluding Impact Of U.S. IRA Legislation Changes; Total Revenues Expected To Grow To €7.5 Billion-€7.6 Billion In 2025 Compared To €7.2 Billion In 2024
- Reuters
Benzinga Newsdesk
PRO
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader
Benzinga Newsdesk